155 QUESTIONS WITH ACCURATE SOLUTIONS
1. What is the recommended device for a patient with mild persistent asthma
who is struggling to use a metered-dose inhaler (MDI) for low dose inhaled
corticosteroid (ICS) administration?
A. A nebulizer
B. A soft-mist inhaler
C. A dry powder inhaler (DPI)
D. A spacer device
2. A patient presents with severe asthma exacerbation and a chest X-ray
shows increased bronchial wall markings and patchy infiltrates. Based on
these findings, what would be the most appropriate next step in
management?
A. Initiate high-dose corticosteroids and consider hospitalization.
B. Discharge the patient with a prescription for a rescue inhaler.
C. Schedule a follow-up appointment in one month.
D. Recommend over-the-counter antihistamines.
3. Explain why immunomodulator biologicals are considered for patients with
severe persistent asthma who are already on multiple medications.
They provide immediate relief of symptoms.
, They target specific pathways in the immune response to reduce
inflammation.
They are the first-line treatment for all asthma patients.
They are less effective than oral corticosteroids.
4. Explain the significance of identifying triggers in asthma management. Why
is this an essential component of a comprehensive asthma care plan?
, Triggers can be ignored as they do not affect asthma severity.
Identifying triggers helps in customizing treatment and
preventing exacerbations.
Triggers are only relevant for children with asthma.
Identifying triggers is less important than medication adherence.
5. Explain how identifying triggers can impact the management of asthma in
patients.
It allows for the complete elimination of asthma.
It helps in tailoring treatment plans and avoiding exacerbations.
It has no significant effect on asthma management.
It only benefits patients with mild asthma.
6. Explain why a soft-mist inhaler might be a better option for a patient with
mild persistent asthma who has difficulty using an MDI.
A. It delivers medication in a more concentrated form.
B. It produces a slower mist that allows for easier inhalation.
C. It requires less coordination than an MDI.
D. It is less expensive than other inhalers.
7. Explain the mechanism by which leukotriene receptor antagonists, such as
montelukast, help in managing asthma symptoms.
They reduce inflammation by inhibiting histamine release.
, They block the action of leukotrienes, which are inflammatory
mediators.
They relax bronchial smooth muscles by stimulating beta receptors.
They increase mucus production to clear airways.